Company Overview - Suzhou Planning's stock closed at 19.89 yuan on July 16, down 4.74%, with a rolling PE ratio of 78.83 times and a total market value of 2.275 billion yuan [1] - The company's main business includes planning design, engineering design, general contracting and management, and smart city services [1] Financial Performance - In the latest quarterly report for Q1 2025, the company achieved operating revenue of 46.2481 million yuan, a year-on-year decrease of 18.42%, and a net profit of 3.2258 million yuan, down 5.65% year-on-year, with a gross profit margin of 23.83% [1] Industry Comparison - The average PE ratio for the engineering consulting service industry is 59.62 times, with a median of 39.55 times, placing Suzhou Planning at 37th in the industry ranking [1] - The static PE ratio for Suzhou Planning is 78.30 times, while the industry average is 71.06 times [2] - The industry median for the price-to-book ratio is 2.40, while Suzhou Planning's is 2.29 [2] Capital Flow - On July 16, the net outflow of main funds for Suzhou Planning was 11.8442 million yuan, with a total outflow of 51.3888 million yuan over the past five days [1]

Company Overview - Wuzhou Medical's closing price on July 16 was 35.05 yuan, down 2.37%, with a rolling PE ratio of 66.73 times and a total market value of 2.383 billion yuan [1] - The company ranks 94th in the medical device industry, which has an average PE ratio of 51.87 times and a median of 37.48 times [1] Shareholder Information - As of June 30, 2025, Wuzhou Medical had 6,407 shareholders, an increase of 102 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] Business Operations - Wuzhou Medical specializes in the research, development, manufacturing, and sales of disposable sterile infusion medical devices, as well as integrated supply of other diagnostic and nursing medical products [1] - Key products include syringes, safety syringes, insulin syringes, infusion sets, blood transfusion sets, and various types of needles and medical masks [1] Financial Performance - In the first quarter of 2025, Wuzhou Medical reported revenue of 104 million yuan, a year-on-year increase of 15.59%, while net profit was 5.6345 million yuan, reflecting a year-on-year decrease of 43.00%, with a gross profit margin of 14.62% [1]

Core Viewpoint - The company, Lifesense Medical, has reported a decline in revenue but a significant increase in net profit, indicating a potential shift in operational efficiency despite market challenges [1][2]. Company Summary - Lifesense Medical's stock closed at 12.66 yuan, up 3.35%, with a rolling PE ratio of 38.89, marking a new low in 84 days and a total market capitalization of 7.339 billion yuan [1]. - The company operates in the medical device sector, focusing on the research, production, sales, and service of medical electronic devices and in vitro diagnostic products [1]. - Key products include critical care monitoring solutions, bedside monitoring solutions, smart vital sign management, various ECG and ultrasound systems, and molecular diagnostic products [1]. Financial Performance - For the first quarter of 2025, the company reported revenue of 420 million yuan, a year-on-year decrease of 5.25%, while net profit reached 65.0882 million yuan, reflecting a year-on-year increase of 68.98% [2]. - The gross profit margin for the company stood at 58.34% [2]. Industry Comparison - The average PE ratio for the medical device industry is 51.87, with a median of 37.48, positioning Lifesense Medical at the 78th rank within the industry [1][2]. - Other companies in the industry have varying PE ratios, with the highest being 19.04 for Antu Biology and the lowest at 10.85 for Jiuan Medical [2].

Group 1 - The core viewpoint of the articles highlights that Zhonggong International's stock closed at 8.46 yuan, down 1.05%, with a rolling PE ratio of 27.88 times and a total market value of 10.468 billion yuan [1] - The average PE ratio for the engineering construction industry is 14.24 times, with a median of 19.89 times, placing Zhonggong International at the 50th position in the industry ranking [1] - In terms of capital flow, Zhonggong International experienced a net outflow of 18.9759 million yuan on July 15, with a total outflow of 46.6535 million yuan over the past five days [1] Group 2 - Zhonggong International's main business includes design consulting and engineering contracting, advanced engineering technology equipment development and application, and engineering investment and operation [1] - The company has received over 300 national and provincial-level scientific and technological achievement awards and holds a national-level first-class engineering design qualification for cableway [1] - The latest quarterly report for Q1 2025 shows that the company achieved an operating income of 2.183 billion yuan, a year-on-year decrease of 7.61%, and a net profit of 131 million yuan, a year-on-year increase of 12.17%, with a sales gross margin of 19.72% [1]

序号股票简称PE(TTM)PE(静)市净率总市值(元)12亚钾国际23.4430.922.43293.85亿行业平均 24.8326.102.47161.97亿行业中值22.3624.461.7279.30亿1云天化8.087.821.76416.92亿2史丹利 11.6912.401.44102.40亿3新洋丰11.7713.291.59174.78亿4云图控股14.5415.271.37122.83亿5兴发集团 16.6515.911.17254.74亿6司尔特16.7414.640.8545.58亿7盐湖股份18.8919.752.44920.73亿8芭田股份 18.9924.462.95100.07亿9东方铁塔20.0321.391.32120.67亿10华昌化工21.1612.481.1365.05亿11四川美丰 21.2814.400.9439.12亿 截至2025年一季报，共有34家机构持仓亚钾国际，其中基金25家、其他8家、社保1家，合计持股数 44568.20万股，持股市值108.84亿元。 来源：金融界 7月15日，亚钾国际今日收盘31.8元，下跌2.15%，滚动市盈率PE（当前股价与前四 ...

7月14日，爱迪特今日收盘43.65元，上涨6.91%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到29.35倍，创26天以来新低，总市值46.52亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均51.90倍，行业中值37.22倍，爱迪特排名 第63位。 截至2025年一季报，共有6家机构持仓爱迪特，其中基金5家、其他1家，合计持股数197.66万股，持股 市值1.09亿元。 爱迪特(秦皇岛)科技股份有限公司的主营业务是口腔修复材料的研发、生产和销售；口腔数字化设备的 设计和销售。公司的主要产品是口腔修复材料、口腔数字化设备。 最新一期业绩显示，2025年一季报，公司实现营业收入2.05亿元，同比18.07%；净利润3127.14万元， 同比34.21%，销售毛利率51.00%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13爱迪特29.3530.912.3146.52亿行业平均 51.9049.564.52107.49亿行业中值37.2237.602.5051.67亿1九安医疗10.4010.510.82175.44亿2英科医疗 11.0611.930.98174. ...

7月14日，通源石油今日收盘5.67元，上涨1.43%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到63.63倍，总市值33.37亿元。 从行业市盈率排名来看，公司所处的采掘行业行业市盈率平均28.99倍，行业中值36.51倍，通源石油排 名第19位。 资金流向方面，7月14日，通源石油主力资金净流入1540.33万元，近5日总体呈流出状态，5日共流出 6972.78万元。 通源石油科技集团股份有限公司的主营业务是公司致力于为油气田开发提供全方位的解决方案和技术服 务。公司的主要产品是射孔销售及服务项目、其他油田服务。 最新一期业绩显示，2025年一季报，公司实现营业收入2.58亿元，同比13.21%；净利润78.27万元，同 比-80.38%，销售毛利率22.53%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13通源石油63.6359.962.4033.37亿行业平均 28.9933.583.35150.58亿行业中值36.5139.083.2952.36亿1海油工程11.0611.390.92246.27亿2海油发展 11.3611.651.53425.92亿3中曼石油11. ...

Group 1 - The core viewpoint of the news is that Yueyang Xingchang's stock has seen a significant increase, with a closing price of 18.37 yuan, up 5.57%, and a rolling PE ratio of 123.18, marking a new low in 155 days [1] - The company's total market capitalization is 6.791 billion yuan, while the average PE ratio in the oil industry is 12.98, with a median of 29.44, placing Yueyang Xingchang at the 19th position in the industry ranking [1][2] - As of March 31, 2025, the number of shareholders in Yueyang Xingchang has increased to 22,331, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Group 2 - Yueyang Xingchang Petrochemical Co., Ltd. specializes in the development, production, and sales of chemical new materials, energy conservation and environmental protection, and petrochemical products, including retail of refined oil [1] - The company's main products include methyl tert-butyl ether, liquefied petroleum gas, propylene, industrial isooctane, ortho-cresol, calcined petroleum coke, and special polypropylene [1] - In the latest quarterly report for Q1 2025, the company achieved an operating income of 1.063 billion yuan, a year-on-year increase of 27.85%, while net profit was 13.6081 million yuan, reflecting a year-on-year decrease of 37.00%, with a gross profit margin of 18.85% [1]

Company Overview - Shanghai MicroPort CardioFlow Medtech Co., Ltd. specializes in the research, production, and sales of interventional medical devices for aortic and peripheral blood vessels [2] - The main products include thoracic aortic stent graft systems, abdominal aortic stent graft systems, intraoperative stents, balloon catheters, and stents [2] Recent Performance - As of the first quarter of 2025, the company reported revenue of 332 million yuan, a year-on-year decrease of 7.23%, and a net profit of 130 million yuan, down 29.66% year-on-year [2] - The sales gross margin stands at 69.61% [2] Market Position - The company's stock closed at 95.92 yuan, with a rolling price-to-earnings (PE) ratio of 26.42, marking a new low in 67 days [1] - The total market capitalization is 11.823 billion yuan [1] - In comparison to the industry, the average PE ratio for the medical device sector is 52.06, with a median of 37.22, placing the company at the 57th position in the industry ranking [1][3] Institutional Holdings - As of the first quarter of 2025, 11 institutions hold shares in the company, including 5 funds, 4 others, 1 brokerage, and 1 social security fund, with a total holding of 56.5791 million shares valued at 5.098 billion yuan [1]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of the company, Da Dongfang, within the medical services industry [1][2] - As of July 11, Da Dongfang's closing price was 5.13 yuan, reflecting a decline of 3.93%, with a rolling PE ratio of 74.22 times and a total market capitalization of 4.539 billion yuan [1] - The average PE ratio for the medical services industry is 44.27 times, with a median of 46.60 times, positioning Da Dongfang at 37th place within the industry [1][2] Group 2 - As of March 31, 2025, Da Dongfang had 82,560 shareholders, a decrease of 10,189 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1] - The main business operations of Da Dongfang include department store retail, Sanfengqiao brand management, and healthcare services, with notable products in these sectors [1] - The latest quarterly report for Q1 2025 shows that the company achieved a revenue of 921 million yuan, a year-on-year decrease of 8.55%, and a net profit of 39.932 million yuan, a year-on-year decline of 78.14%, with a sales gross margin of 19.46% [1]